Website is intended for physicians



Background: the optimal method for radiological diagnosis of prostate cancer (PCa) in planning multifocal biopsy is multiparametric magnetic resonance imaging (mpMRI)

Aim: was to improve the diagnosis of clinically significant PCa (csPCa) in patients with a negative primary biopsy, proceeding from mpMRI findings analysis based on results of the repeated procedure (24 cores) with targeted sampling of suspicious lesions.

Materials and methods: 732 patients were examined, 714 of them had been included in data of analysis. Prostatic mpMRI found suspicious foci with PI-RADS 3-5 in 396/714 (55.5%) patients. Results: The detection of PCa with a Gleason score of >7, PI-RADS 4 and 5 accounted for 65.9% and 80.0%, respectively Diagnostic sensitivity of mpMRI with a PI-RADS >4 in the diagnosis of PCa in patients with suspicious foci (n=396) was 83.6%, specificity - 84.9%; in the whole of 714 patients it was 46.4% and 86.7%, with a Gleason score of >7 - 75.3% and 89.3%, respectively In 73/290 (25.2%) patients with PI-RADS 3-5, PCa was detected in a systematic rather than in targeted biopsy, 17/73 (23.3%) of them having Gleason score >7. In 70/318 (22.0%) patients with PI-RADS 1-2, PCa was detected in systematic biopsy, in 11/70 (15.7%) cases Gleason score being >7.

Conclusion: mpMRI diagnostic accuracy for csPCa in patients with negative primary biopsy making it possible to refrain from repeated biopsy in males with PI-RADS 1-3; if repeated biopsy is necessary, the systematic one may be recommended.



1.      World Health Organization. International Agency for Research on Cancer. Cancer today. Available at: (accessed 31 July 2018).

2.      Okeanov AE, Moiseev PI, Levin LF. Statistics of oncologic diseases in the Republic of Belarus (2007-2016). Minsk. 2017: 286 [In Russ].

3.      Mottet N, Bellmunt J, Bolla M. et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur. Urol. 2017; 71 (4): 618-629.

4.      Standardized indicators of oncoepidemiological situation 2016. Evraziyskiy onkologicheskiy zhurnal. 2018; 6(2). Avaiable at: (accessed 31 July 2018) [In Russ].

5.      Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. of Oncol. 2015; 26 (suppl. 5): v69-v77.

6.      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™. Prostate Cancer. 2018; Ver. 3. Available at: (accessed 31 July 2018).

7.      Karman AV, Leusik EA. Comprehensive diagnostics for prostate cancer patients with negative primary biopsy. Early findings of a prospective study. Onkologicheskiy zhurnal. 2013; 7 (4): 65-71 [In Russ].

8.      Karman AV, Leusik EA. Diagnostic potential of PI-RADS for patients with negative results of initial multifocal biopsy. Onkologicheskii zhurnal. 2014; 8 (2): 20-27 [In Russ].

9.      Futterer JJ, Briganti A, de Visschere P. et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur. Urol. 2015; 68 (6): 1045-1053.

10.    Karman AV, Krasny SA, Leusik EA. et al. Our experience in employing the second version of PI-RADS scale in prostate cancer diagnosis in patients with negative initial multifocal biopsy. Onkologicheskiy zhurnal. 2015; 9 (2): 63-69 [In Russ].

11.    Kasel-Seibert M, Lehmann T, Aschenbach R. et al. Assessment of PI-RADS v2 for the Detection of Prostate Cancer. Eur. J. Radiol. 2016; 85 (4): 726-731.

12.    Moldovan PC, van den Broeck T, Sylvester R. et al. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur. Urol. 2017; 72 (2): 250-266.

13.    Karman AV, Krasnyy SA, Shimanets SV. Targeted histology sampling from atypical small acinar proliferation area detected by repeat transrectal prostate biopsy. Onkourologiya. 2017; 3 (1): 91-100 [In Russ].

14.    Boesen L, Noergaard N, Chabanova E. et al. Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy. Scand. J. Urol. 2015; 49 (1): 25-34.

15.    Junker D, Schwfer G, HeideggerI. et al. Multiparametric magnetic resonance imaging/transrectal ultrasound fusion targeted biopsy of the prostate: preliminary results of a prospective single-centre study. Urol. Int. 2015; 94 (3): 313-318.

16.    Prostate Imaging Reporting and Data System (PI-RADS). Available at: Safety/Resources/PIRADS/ (accessed 31 July 2018).

17.    Bjurlin MA, Meng X, Le Nobin J. et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J. Urol. 2014; 192 (3): 648-658.

18.    Franiel T, Stephan C, Erbersdobler A. et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding - multiparametric MR imaging for detection and biopsy planning. Radiology. 2011; 259 (1): 162-172.

19.    Karman AV, Leusik EA., Dudarev VS. Saturation transrectal biopsy in prostate cancer diagnosing in men with negative primary multifocal biopsy. Onkologicheskij zhurnal. 2014; 8 (31): 31-40 [In Russ].

20.    Simmons LAM., Kanthabalan A, Arya M. et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. Br. J. Cancer. 2017; 116 (9): 1159-1165.

21.    Brown LC, Ahmed HU, Faria R. et al. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. Health Technol. Assess. 2018; 22 (39): 1-176. (АНГИОЛОГИЯ.ру) - портал о диагностике и лечении заболеваний сосудистой системы